seed
Stage
2020
Founded
2
Investors
About
Tribune Therapeutics is a biotechnology company developing novel small molecule therapies for chronic inflammatory diseases. Their lead program targets inflammatory bowel disease (IBD) with a first-in-class inhibitor.
Explore Tribune Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.